FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a rodent for producing a humanized polypeptide of the lymphocyte-activation gene 3 (Lag-3), wherein the rodent gene comprises a humanized Lag-3 gene in the endogenous locus Lag-3, a method for producing said gene, and also to the tissue and cell thereof. An embryonic rodent stem (ES) cell for producing a humanized Lag-3 polypeptide and a rodent embryo containing the above-mentioned cell are also disclosed.
EFFECT: invention enables effectively assessing the antitumor effectiveness and pharmacokinetic properties of a medicinal agent which is purposely acting on human LAG-3.
19 cl, 9 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANIMALS OTHER THAN HUMANS HAVING A HUMANIZED GENE 1 OF PROGRAMMED CELL DEATH | 2015 |
|
RU2735958C2 |
| NON-HUMAN ANIMALS HAVING HUMANIZED GENE OF DIFFERENTIATION CLUSTER 274 | 2015 |
|
RU2711729C2 |
| ANIMALS OTHER THAN A HUMAN HAVING A STRUCTURED ANGPTL8 GENE | 2017 |
|
RU2742354C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2703139C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2788523C2 |
| HUMANISED ANIMALS BY C5 AND C3 | 2015 |
|
RU2713327C2 |
| NON-HUMAN ANIMALS HAVING HUMANIZED SIGNAL-REGULATORY PROTEIN GENE | 2014 |
|
RU2671166C2 |
| ANIMALS OTHER THAN HUMANS HAVING A HUMANISED CLUSTER GENE OF DIFFERENTIATION 47 | 2015 |
|
RU2728412C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
